Valencell was founded with the vision of empowering people to live longer, healthier lives through validated physiological insights. To this end, we develop consumer-friendly digital health solutions that aim to improve health outcomes and prevent chronic disease for hundreds of millions of people world-wide. At the heart of these digital health solutions is our proprietary biometric sensor technology and machine learning analytics, protected by 150+ awarded patents, which enables medical-grade physiological monitoring and health management via wearable devices in popular consumer form-factors. A key advancement spearheaded by Valencell is the development of the world’s first cuffless, calibration-free blood pressure monitoring solution that can provide a robust, comfortable, and convenient over-the-counter alternative to the traditional blood pressure cuff.
Contact us for more detail on how we might be able to collaborate together.
As a team of scientists – optical, mechanical, electrical engineers, and exercise scientists – we do extensive validation of our technology in our world-class Biometrics Lab.Then we have independent research institutions conduct independent validation. Our technology has been validated by the Duke Center for Living, North Carolina State University, the North Carolina Research Campus and a fellow of the American College of Sports Medicine, among others.
Founded in 2006, Valencell has become the leading innovator in high-performance biometric sensor technology for wearables and hearables. We power more biometrics wearables on the market than any other company in the world. We provide our customers with the most advanced, fully validated biometrics available today, including continuous heart rate, RR interval, cardiac efficiency, V02 max, blood pressure, and more.
We have a long history of innovation in biometric wearables and have a highly-cited patent portfolio in wearable biometrics and PPG. And we’re not stopping – we continue to invent new technology every day with over 50 additional patents pending, which is driving a hardware and software roadmap you can believe in.
In 2018, Valencell partnered with Sonion, the global leader in micro acoustic and micro mechanical technologies and solutions for hearing instruments and specialty earphones, expands the boundaries for the use of biometric sensors in the ear. Through the partnership, Valencell provides the industry’s most advanced biometric sensor modules for hearables and wearables, which Sonion will optimize for size, power consumption and cost for in-ear and on-ear applications. The partnership focuses on designing, developing and manufacturing biometric sensing ear modules for the medical, hearing health, consumer and professional communications markets.
In 2020, Halma, the global group of life-saving technology companies, took a minority equity stake and a seat on Valencell’s board, which enabled the company to accelerate growth opportunities. The partnership also brings new capabilities to companies within Halma’s Medical sector already operating in this market niche. SunTech Medical, a Halma company, has signed a collaboration agreement with Valencell to co-operate on a clinical-grade blood pressure technology augmented with a PPG sensor.
We’ve also raised more than $40 million in venture funding from TDF Ventures, GII Tech, WSJ Joshua Fund, Sonion, and Halma plc, and secured more than $3 million in grants.